Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer’s Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine

Cabral, 2008, CB2 receptors in the brain: Role in central immune function, Br J Pharmacol, 153, 240, 10.1038/sj.bjp.0707584

Benito, 2010, Cannabinoid CB2 receptors in human brain inflammation, Br J Pharmacol, 153, 277, 10.1038/sj.bjp.0707505

Van Sickle, 2005, Identification and functional characterization of brainstem cannabinoid CB2 receptors, Science, 310, 329, 10.1126/science.1115740

Viscomi, 2009, Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway, J Neurosci, 29, 4564, 10.1523/JNEUROSCI.0786-09.2009

Atwood, 2010, CB2: A cannabinoid receptor with an identity crisis, Br J Pharmacol, 160, 467, 10.1111/j.1476-5381.2010.00729.x

Callén, 2012, Cannabinoid receptors CB1 and CB2 form functional heteromers in brain, J Biol Chem, 287, 20851, 10.1074/jbc.M111.335273

Zhang, 2014, Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice, Proc Natl Acad Sci U S A, 111, E5007, 10.1073/pnas.1413210111

Dhopeshwarkar, 2014, CB2 Cannabinoid receptors as a therapeutic target— what does the future hold?, Mol Pharmacol, 86, 430, 10.1124/mol.114.094649

Ferrer, 2012, Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia, Prog Neurobiol, 97, 38, 10.1016/j.pneurobio.2012.03.005

Selkoe, 2012, Preventing Alzheimer’s disease, Science, 337, 1488, 10.1126/science.1228541

Benito, 2003, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains, J Neurosci, 23, 11136, 10.1523/JNEUROSCI.23-35-11136.2003

Ramírez, 2005, Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation, J Neurosci, 25, 1904, 10.1523/JNEUROSCI.4540-04.2005

Solas, 2013, CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients, Neurobiol Aging, 34, 805, 10.1016/j.neurobiolaging.2012.06.005

Savonenko, 2015, Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: Immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation, PLoS One, 10, e0129618, 10.1371/journal.pone.0129618

Tolón, 2009, The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages, Brain Res, 1283, 148, 10.1016/j.brainres.2009.05.098

Martín-Moreno, 2012, Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice, J Neuroinflammation, 9, 8, 10.1186/1742-2094-9-8

Wu, 2013, Activation of the CB2 receptor system reverses amyloid-induced memory deficiency, Neurobiol Aging, 34, 791, 10.1016/j.neurobiolaging.2012.06.011

van der Stelt, 2006, Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels, Cell Mol Life Sci, 63, 1410, 10.1007/s00018-006-6037-3

Esposito, 2007, Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: In vitro and in vivo evidence, J Pharmacol Exp Ther, 322, 1144, 10.1124/jpet.107.121566

Fakhfouri, 2012, WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway, Neuropharmacology, 63, 653, 10.1016/j.neuropharm.2012.05.013

Aso, 2013, CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice, J Alzheimers Dis, 35, 847, 10.3233/JAD-130137

Koppel, 2014, CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease, Mol Med, 20, 29, 10.2119/molmed.2013.00140.revised

Aso, 2015, Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice, J Alzheimers Dis, 43, 977, 10.3233/JAD-141014

Casarejos, 2013, Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy, J Alzheimers Dis, 35, 525, 10.3233/JAD-130050

Cao, 2014, The potential therapeutic effects of THC on Alzheimer’s disease, J Alzheimers Dis, 42, 973, 10.3233/JAD-140093

Martín-Moreno, 2011, Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer’s disease, Mol Pharmacol, 79, 964, 10.1124/mol.111.071290

Cheng, 2014, Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice, Psychopharmacology (Berl), 231, 3009, 10.1007/s00213-014-3478-5

Cheng, 2014, Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice, J Alzheimers Dis, 42, 1383, 10.3233/JAD-140921

Huestis, 2005, Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol, Handb Exp Pharmacol, 168, 657, 10.1007/3-540-26573-2_23

Pertwee, 2008, The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydro-cannabivarin, Br J Pharmacol, 153, 199, 10.1038/sj.bjp.0707442

Russo, 2011, Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects, Br J Pharmacol, 163, 1344, 10.1111/j.1476-5381.2011.01238.x

Borchelt, 1997, Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins, Neuron, 19, 939, 10.1016/S0896-6273(00)80974-5

Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor, Eur J Pharmacol, 396, 141, 10.1016/S0014-2999(00)00211-9

Aso, 2012, CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice, J Alzheimers Dis, 30, 439, 10.3233/JAD-2012-111862

Jin, 2011, Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration, Proc Natl Acad Sci U S A, 108, 5819, 10.1073/pnas.1017033108

García-Gutiérrez, 2013, Synaptic plasticity alterationsassociated with memory impairment induced by deletion of CB2 cannabinoid receptors, Neuropharmacology, 73, 388, 10.1016/j.neuropharm.2013.05.034

Schmöle, 2015, Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer’s disease mouse model, Neurobiol Aging, 36, 710, 10.1016/j.neurobiolaging.2014.09.019